Pacific Edge launches capital raise of NZ$24 million

8 MAY 2026


PACIFIC EDGE LAUNCHES CAPITAL RAISE OF NZ$24 MILLION
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB, the
‘Company’) today announces an offer to raise up to NZ$24 million at NZ$0.170 per share
consisting of a placement of NZ$18 million new ordinary shares to eligible investors and an
offer of NZ$6 million new shares to retail investors with an ability to accept over subscriptions.
The capital raising is aimed at ensuring Pacific Edge has the resources and capacity to regain
Medicare coverage, achieve reimbursement for its tests, and to position the business for
growth.
In conjunction with the capital raising, Pacific Edge is also announcing unaudited financial
information for the 12 months to 31 March 2026 (FY 26). That information shows a reduction
in revenue due to Medicare ending reimbursement of Cxbladder following the 2025 non-
coverage determination, but substantial progress to contain costs in the business to manage
the Medicare uncertainty and preserve cash.
UNAUDITED PRELIMINARY FY 26 FINANCIAL INFORMATION
1

FY 26 operating revenue fell to $11.5 million from $21.8 million in FY 25 after the Medicare
non-coverage determination saw a 21.4% reduction in US total laboratory throughput (TLT) to
18,784 tests from 23,885 tests in FY 25. The fall in US volumes was amplified by the disruption
of transitioning US customers from Cxbladder Detect to Triage and the challenges of selling a
product not covered by Medicare. APAC volumes for FY 26 increased 7.9% to 5,406.
Pacific Edge has made good progress throughout the year to manage its costs given the
Medicare uncertainty. It has taken these steps recognising the need to balance costs against
protecting the core assets of the business to preserve the Company’s ability to scale
commercially after coverage is regained.
Total expenses fell to $49.3 million from $54.6 million in FY 25. Capital conservation initiatives
saw a 27.7% fall in average 2H 26 monthly cash burn to $2.4 million per month from $3.3
million per month in 1H 26. The net loss for FY 26 increased to $35.7 million from $29.9 million
in FY 25.
Cash and cash equivalents on 31 March 2026 were $7.8 million against $22.1 million on 30
September 2025 and $22.6 million on 31 March 2025.
Further commentary on this unaudited FY 26 financial information is set out in a presentation
released to the NZX and ASX today. Pacific Edge intends to release its audited FY 26 financial
results on Monday, 25 May 2026.
EQUITY RAISE TO CAPITALISE ON COMMERCIAL MILESTONES
Pacific Edge expects Novitas
2
to release a draft Local Coverage Determination (LCD) for
hematuria evaluation, that includes coverage for Triage, and potentially Triage Plus, any time

1
FY 26 financial information in this announcement is taken from management accounts and has not been audited.
Following the audit process, the FY 26 financial information in this announcement may change. Pacific Edge expects
to release its audited FY 26 financial results on Monday, 25 May 2026.
2
Novitas is the Medicare administrative contractor with responsibility for Pacific Edge’s US laboratory.

2

before September 2026. This expectation follows a Contractor Advisory Committee (CAC)
meeting in the US, hosted by Novitas on 19 February 2026, that provided an evidence-based
mandate for the coverage of urine-based biomarkers, citing Pacific Edge’s peer-reviewed
Cxbladder publications.
A new LCD for hematuria evaluation would likely distinguish hematuria patients as eligible for
Cxbladder Triage testing from the cancer patients in the non-coverage LCD ‘Genetic Testing
in Oncology: Specific Tests’ (L39365) effective since April 2025. If Novitas issues a draft LCD,
Pacific Edge will engage with Novitas to seek reimbursement on a claim-by-claim basis for
patients making this distinction supported by medical necessity documentation for Triage and
potentially Triage Plus. Reimbursement would assist with increasing revenue and reducing
average monthly cash burn below the current target of NZ$2.5 million per month for FY 27
(reduced from an average of NZ$2.85 million per month in FY 26).
The publication of a draft LCD is followed by a ‘notice and comment’ period (minimum of 45
days), before Novitas addresses comments and finalizes the LCD. Once a final LCD is
published
3
, it will take a further minimum of 45 days for the final LCD to become effective. Final
coverage policy from Medicare is expected to remove barriers to establishing medical policy
with commercial payers and unlock greater revenue from them.
Reflecting the significant potential and uplift in the prospects for Pacific Edge that will follow a
positive Medicare determination, the Company is today launching its capital raising. The new
equity is aimed at providing Pacific Edge with the resources to:
 Strengthen its balance sheet to support ongoing operations and growth;
 Support the Company to achieve Medicare re-coverage;
 Continue evidence generation; and
 Continue product development and innovation.
Chairman Simon Flood said: “Pacific Edge is on the cusp of a commercial inflection point.
Backed by robust clinical evidence, the endorsement of our tests in clinical guidelines, and
growing momentum in clinical opinion, we have firmly established ourselves as the first mover
and market leader in bladder cancer diagnostics.
“The new capital we are seeking today will allow us to consolidate this position. It will support
the Company and its operations to regain Medicare coverage and assist our move towards the
broader adoption of our tests by commercial payers in the US and further afield. We are
determined not to lose that momentum. All of Pacific Edge’s Directors intend to take part in the
equity raising. We encourage you to support this offer.”
Pacific Edge Chief Executive Dr Peter Meintjes said: “We have an opportunity to entrench our
first-mover advantage in the use of urine biomarkers, and the moat we have created. This

3
Novitas may withdraw, rather than finalize, the draft LCD. Novitas must finalize or withdraw a draft LCD within 365
days of publishing the initial draft. Pacific Edge has no control over the draft publication nor the final publication, nor
the timing of the publication.

3

position will be entrenched with a new LCD for hematuria evaluation, that includes coverage
for Triage and potentially Triage Plus.
“The capital we are seeking today will set a clear path to reimbursement for our tests after the
receipt of the draft LCD, support continued investment in our clinical evidence and invest in
product innovation. We are excited by the growth we see ahead, and we encourage
shareholders to support us to take advantage of these opportunities.”
Further details of the capital raise have been included in a presentation also released to the
NZX and ASX today.
OFFER DETAILS:
Offer size and
structure
An equity raising, comprising:
- A NZ$18 million Placement, equating to 10.1% of Pacific Edge’s current
market capitalisation
- A NZ$6 million Retail Offer (with the ability to accept oversubscriptions at the
Board’s discretion)
Placement offer
details
- The Placement Offer Price will be NZ$0.170 per share representing:
o 2.3% discount to the last closing price of NZ$0.174 on 8 May 2026
o 2.0% discount to the five-day VWAP of NZ$0.1735
1

Retail Offer details
- Pacific Edge is offering up to NZ$6 million of newly issued ordinary shares
(with the ability to accept oversubscriptions at the Board’s discretion) to
Pacific Edge’s eligible existing shareholders resident in New Zealand (up to a
maximum of NZ$50,000 per shareholder) under a Retail Offer (predominantly
structured as a share purchase plan)
- The Retail Offer will be priced at the Placement Price (being NZ$0.170 per
share)
Commitments
- Pacific Edge’s Chair, Simon Flood, intends to apply for NZ$500,000 of shares
under the Placement
- All other Pacific Edge directors also intend to participate in the Offer
Ranking
- The new shares to be issued under both the Placement and Retail Offer will
on allotment rank equally in all respects with Pacific Edge’s existing ordinary
shares on issue
Non underwritten
- Neither the Placement nor Retail Offer are underwritten
1
Volume weighted average price for the period 4 May 2026 to 8 May 2026 (dates inclusive)

TIMETABLE
Placement
Placement conducted under trading halt 11 to 12 May 2026
Announcement of the Placement results and trading halt lifted on the NZX
1
13 May 2026
Settlement, allotment and trading of Placement shares on NZX and ASX
commence
15 May 2026
Retail Offer
Record date 7:00pm (NZST) on 8 May 2026
Retail Offer opens and documentation sent to eligible shareholders 14 May 2026
Retail Offer closes 28 May 2026
Announcement of results of Retail Offer 3 June 2026
Settlement, allotment and commencement of trading of Retail Offer shares
on NZX
4 June 2026
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

4

Pacific Edge is holding a conference call for investors analysts and the media at 11.00am
(NZST). This investor briefing will be available via webcast at the following link:
www.virtualmeeting.co.nz/pebic26 or by phone on the following toll-free numbers:  
Conference ID: 2639914
Australia - Toll (Sydney) +61 2 8088 0946
Australia - Toll Free +61 1800 571 226
New Zealand - Toll Free 0800 450 012
New Zealand - Auckland +649 887 4636
USA & Canada - Toll-Free (800) 715-9871
United Kingdom - Toll-Free +44 800 260 646
For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: 022 032 1263
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the Company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with microhematuria and those being monitored for
recurrent disease. The tests help improve the overall patient experience, while prioritizing time
and clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
25 peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.

---

Capital Raising Presentation
Dr Peter Meintjes
Chief Executive Officer
Grant Gibson
Chief Financial Officer
8 May 2026
1

This presentation has been prepared by Pacific Edge Limited (PEL) solely to provide
interested parties with further information about PEL and its activities at the date of
this presentation in connection with the proposed capital raising outlined in this
presentation.
Information of a general nature
The information in this presentation is of a general nature and does not purport to be
complete nor does it contain all the information which a prospective investor may
require in evaluating a possible investment in PEL or that would be required in a
product disclosure statement, prospectus or other disclosure documentfor the
purposes of the New Zealand Financial Markets Conduct Act 2013 (FMCA) or the
Australian Corporations Act 2001. PEL is subject to a disclosure obligation that
requires it to notify certain material information to NZX Limited (NZX) and ASX
Limited (ASX) forthe purpose of that information being made available to participants
in the market and that information can be found by visiting
www.nzx.com/companies/PEBand www2.asx.com.au/markets/company/PEB. This
presentation should be read in conjunction with PEL’s other periodic and continuous
disclosure announcements released to NZXand ASX.
NZX and ASX
New shares issued under the capital raising will be quoted on the NZX Main Board
following completion of the capital raising, and an application will be made by PEL to
be quoted on the ASX. Neither NZX nor ASX accepts any responsibility for any
statement in this presentation. NZX is a licensed market operator, and the NZX Main
Board is a licensed market under the FMCA.
Not an offer
This presentation is not a prospectus or product disclosure statement or other
offering document under New Zealand or Australian law or any other law (and will
not be filed with or approved by any regulatory authority in New Zealand, Australia or
any other jurisdiction). This presentation is for information purposes only and is not
an invitation or offer of securities for subscription, purchase or sale in any
jurisdiction.Any decision to acquire new shares under the capital raising should be
made on the basis of all information provided in relation to the capital raising and
PEL’s other periodic and continuous disclosure announcements released to NZX and
ASX.
Not financial product advice
This presentation does not constitute legal, financial, tax, financial product advice or
investment advice or a recommendation to acquire PEL securities and has been
prepared without taking into account the objectives, financial situation or needs of
investors. Before making an investment decision, prospective
investors should consider the appropriateness of the information having regard to
their own objectives, financial situation and needs and consult an NZX Firm, solicitor,
accountant or other professional advisor if necessary.
Forward-looking statements
This presentation may contain forward-looking statements that reflect PEL’s current
views with respect to future events. Forward-looking statements, by their very nature,
are not guarantees of future outcomes and involve inherent risks and uncertainties.
Many of those risks and uncertainties are matters which are beyond PEL’s control and
could cause actual results to differ from those predicted. Variations could either be
materially positive or materially negative. The information is stated only as at the
date of this presentation. Except as required by law or regulation (including the NZX
Listing Rulesand ASX Listing Rules), PEL undertakes no obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise. To the maximum extent permitted by law, the directors of PEL,
PEL and any of its related bodies corporate and affiliates, and their respective
officers, partners, employees, agents, associates and advisers do not make any
representation or warranty, express or implied, as to the accuracy, reliability or
completeness of such information, or the likelihood of fulfilment of any forward-
looking statement or any event or results expressed or implied in any forward-looking
statement, and disclaim all responsibility and liability for these forward-looking
statements (including, without limitation, liability for negligence).
Financial information
All dollar values are in New Zealand dollars unless otherwise stated. This presentation
includes unaudited financial information for Pacific Edge for its financial year ended
31 March 2026 (FY 26). The FY 26 financial information is taken from management
accounts and has not been audited by Pacific Edge's external auditors. Following the
audit process, FY 26 financial information in this presentation may change. Pacific
Edge expects to release its audited financial statements for FY 26 on 25 May 2026.
This presentation should be read in conjunction with, and subject to, the explanations
and views of future outlook on market conditions, earnings and activities given in
recent announcements to the NZX and ASX.
Non-GAAP financial information
This presentation contains certain financial measures that are “non-GAAP financial
information” under the New Zealand Financial Markets Authority Guidance Note on
disclosing non-GAAP financial information and “non-IFRS financial information” under
the ASIC Regulatory Guide on disclosing non-IFRS financial information (and
potentially under other regulatory guidelines or rules).Such financial information and
financial measures (including Cash Burn) do not have standardised meanings
prescribed under NZ IFRS or IFRS and therefore, may not be comparable to similarly
titled measures presented by other entities, and should not be construed as an
alternative to other financial measures determined in accordance with NZ IFRS, or
IFRS.)
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of value and
fractions in this presentation are subject to the effect of rounding. Accordingly, the
actual calculation of these figures may differ from the figures set out in this
presentation.
Past performance
Investors should note that past performance, including past share price performance,
cannot be relied upon as an indicator of (and provides no guidance as to) future PEL
performance, including future financial position or share price performance.
Investment risk
An investment in securities of PEL is subject to investment risk and other known and
unknown risks, some of which are beyond the control of PEL. Refer to Section 5 “Key
Risks” for a non-exhaustive summary of certain key risks associated with PEL and the
capital raising. Neither PEL nor any other person named in this presentation
guarantees the performance of PEL or any particular return on any securities of PEL.
Distribution of presentation
This presentation must not be distributed in any jurisdiction to the extent that its
distribution in that jurisdiction is restricted or prohibited by law or would constitute a
breach by PEL of any law. The distribution of this presentation in other jurisdictions
outside New Zealand may be restricted by law. Any recipient of this presentation who
is outside New Zealand must seek advice on and observe any such restrictions. Any
failure to comply with such restrictions may contravene applicable securities laws.
None of PEL, any person named in the presentation or any of their affiliates accept or
shall have any liability to any person in relation to the distribution or possession of
this presentation from or in any jurisdiction.
Disclaimer
To the maximum extent permitted by law, none of PEL and its respective
shareholders, directors, officers, partners, employees, agents and advisers makes any
representation or warranty, express or implied, as to the materiality, currency,
accuracy, reliability or completeness of information in this presentation; and none of
them shall have any liability (including for negligence) for:
•any errors or omissions in this presentation; or
•any failure to correct or update this presentation, or any other written or oral
communications provided in relation to this presentation; or
•any claim, loss or damage (whether foreseeable or not) arising from the use of
any information in this presentation or otherwise arising in connection with this
presentation or the information contained in it.
By receiving this presentation, you agree to the above terms and conditions.
IMPORTANT NOTICE AND DISCLAIMER
2

1. PACIFIC EDGE OVERVIEW
3

EXECUTIVE SUMMARY
SIGNIFICANT VALUE CREATION OPPORTUNITIES, SUPPORTED BY PRUDENT CAPITAL MANAGEMENT
KEY SHORT-TERM CATALYSTCLINICAL EVIDENCESCIENCE, TECH AND IP
Draft LCD for Triage & potentially Triage Plus
expected anytime before September 2026.
Final LCD expected anytime before March
2027
1
. Intention to leverage the draft LCD to
seek claim-by-claim reimbursement to drive
revenue prior to final effective coverage
Cxbladder tests are supported by a robust
portfolio of clinical evidence, and the AUA has
recognized Cxbladder Triage with a ‘Grade A’
evidence rating –the only urine biomarker to
achieve that rating
Cxbladder tests are patented non-invasive
urine tests that deliver proven clinical,
economic and patient value
FOCUSED PATH TO PROFITABILITYPRUDENT CAPITAL MANAGEMENTSUBSTANTIAL MARKET OPPORTUNITY
Triage Plus has confirmed Medicare pricing
at US$1,328/test (increased from US$760
for Triage).Post-coverage focuson sales
force efficiency, implementing clinical
pathways at institutional accounts and
scaling throughput beyond historic levels
Cash burn actively reduced in 2H 26 vs 1H
26. Further phased cash management
activities have commenced. Balancing cash
preservation with maintaining core
capabilities for commercial scaling post-
coverage
The primary symptom of bladder cancer is
hematuria with ~7m diagnoses each year in
the US driving a global market opportunity
of US$10.8 billion
4
Definitions: AUA = American Urological Association, LCD = local coverage determination.
1. It is also open to Novitas to retire, rather than finalize, the draft LCD. Novitas must publish the final LCD or retire the draft LCD within 365 days after publishing a draft LCD

CAPITAL RAISING OVERVIEW
Pacific Edge Limited (NZX/ASX:PEB) (Pacific Edgeor the Company) is a cancer diagnostics company that develops and commercializes non-invasive bladder
cancer diagnostic and prognostic tests, sold primarily under the “Cxbladder” brand
The Company focuses on genomic urine biomarker tests that support both detection of new bladder cancer in patients presentingwith hematuria and
surveillance of patients with known or suspected recurrent disease
These tests help clinicians improve patient experience whilst optimizing workflow and efficiency
Pacific Edge
Summary
A Contractor Advisory Committee (CAC) meeting hosted by Novitas on 19 February 2026 provided an evidence-based mandate for the coverage of urine-
based biomarkers, regularly citing Cxbladder publications (see Slide 14)
Pacific Edge currently expects Novitas to publish a draft Local Coverage Determination (LCD) for hematuria evaluation, that includes coverage for Triage,
and potentially Triage Plus, anytime before September 2026. Publishing a draft is followed by ‘notice and comment’ (minimum of 45 days), before then
addressing the comments and finalizing. Once finally published, the LCD takes a further 45 days for the final LCD
1
to become effective
Pacific Edge intends to seek claim-by-claim reimbursement for Triage, and potentially Triage Plus, supported by medical necessity documentation after the
publication of the draft LCD, documenting these tests for hematuria patients (not only cancer patients). This is supported by the AUA microhematuria
guideline. Reimbursement would assist with increasing revenue and reducing cash burn between the draft and final-effective LCD
Medicare Coverage
Update
Pacific Edge has taken several actions during FY 26 to reduce monthly average cash burn to NZ$2.4m for 2H 26, down from NZ$3.3m for 1H 26
Pacific Edge has made reductions through working capital optimization, phasing and prioritizing R&D and clinical studies expenses, deferring CAPEX,
reducing headcount and not backfilling departures in the commercial team
In FY 27, Pacific Edge has commenced further phased reductions towards a target monthly average cash burn of NZ$2.5m vs NZ$2.85mfor FY 26 and
further prioritization of R&D and clinical studies expenses, travel reduction and shifting discretionary cash compensation toequity awards
Pacific Edge is balancing cash preservation measures with protecting core assets of the business to preserve our ability to scale commercially after
Medicare re-coverage
Cash Preservation
Measures
1. Novitas may retire, rather than finalize, the draft LCD. Novitas must publish the final LCD or retire the draft LCD within 365 days after publishing a draft LCD
5

CAPITAL RAISING OVERVIEW (CONTINUED)
Anticipated publication of the draft LCD with clear policy language that demonstrates medical necessity of CxbladderTriage and potentially Triage Plus
Leveraging the draft LCD to seek claim-by-claim reimbursement from Novitasfor hematuriatesting that would assist with increasing revenue and reducing
cash burn between the draft and final-effective LCD
Final coverage policy from Medicare expected to unlock revenue from Commercial Payers by 1) removing a key reason to deny, 2)providing language that
commercial payers can adopt in their own policies and 3) leveraging State Biomarker Laws
1
to mandate payment from commercial payers
Pacific Edge is currently targeting to submit CxbladderSurveillance Plus for a CPT-PLA
2
code by 9 December 2026. If that date is achieved, Pacific Edge
currently expects claim-by-claim reimbursement from July 2027 by Novitasat provisional local pricing once the code is added to A58917, leading to
additional US revenue during FY 28
Te Whatu Ora / Health New Zealand is considering Cxbladderfor a National Clinical Pathway for hematuriaevaluation in 2026
Mid-Atlantic Permanente Medical Group has begun a 150-sample Pilot Study for CxbladderTriage mirroring the protocol from Southern California, which if
successful, may lead to future expansion within the Kaiser Permanente Health System to the Mid-Atlantic region covering 800k lives
Key Upcoming
Milestones /
Catalysts
FY 26 operating revenue fell to $11.5 million from $21.8 million in FY 25 after non-coverage determination ended Medicare reimbursement and US total
laboratory throughput (TLT) fell 21.4% to 18,784 tests from 23,885. APAC improved revenue with TLT rising 7.9% to 5,406
Total expenses fell to $49.3 million from $54.6 million in FY25 with capital conservation initiatives reducing average 2H 26 monthly cash burn 27.7% to $2.4
million per month from $3.3 million in 1H 26. Further capital preservation initiatives post financial year end are targeting a monthly average cash burn of
NZ$2.5m for FY 27
Cash and cash equivalents at 30 April 2026 of $5.1m. Cash and cash equivalents at 31 March 2026 (FY) of $7.8m and $22.1m at 30 September 2025 (HY)
Net loss increased to $35.7 million from $29.9 million in FY 25
Unaudited FY 26
financial
information
3
demonstrates
capital discipline
Pacific Edge is conducting a NZ$24 million placement and retail offer of new Pacific Edge ordinary shares (the Offer) with fundsused tostrengthen its
balance sheet to support ongoing operations and growth, support the company to achieve Medicare re-coverage, and continue evidence generation,
product development and innovation
Offer price of NZ$0.170 per share (Offer Price), which represents a 2.3% discount to the last traded price on NZX on 8 May 2026 of NZ$0.174
Post successful completion of the Offer, Pacific Edge will have available funding of NZ$29.1 million
4
Capital Raising to
Advance
Commercialisation
1. State Biomarker Laws have been adopted in multiple states that mandate commercial payers to follow Medicare Policy https://www.fightcancer.org/what-we-do/access-biomarker-testing
2. CPT-PLA: Current Procedural Terminology Proprietary Laboratory Analyses
3. FY 26 financial information is taken from management accounts and has not been audited. Following the audit process, FY 26 financial information in this presentation may change. Pacific Edge
expects to release its audited financial statements for FY 26 on 25 May 2026
4. Available funding is based on cash balance of NZ$5.1 million as at 30 April 2026 plus assumed Offer proceeds (before Offer costs) of NZ$24 million. Further details on capital raising, see Slide 23
6

UNAUDITED FY 26 FINANCIAL INFORMATION: CASH BURN REDUCED ON 1H 26
1
-$35.7M
NET LOSSAFTER
TAX +19.3%
on FY 25
US Total Tests
2
18,784,
-21.4% on FY 25;
APAC Total Tests
2
5,406 +7.9% on FY 25
2H 26 Net Loss After Tax
($16.6m) -13.2% on 1H 26
amid capital preservation
initiatives
2H 26 Operating Revenue
$5.6m –6.4% on 1H 26;
Total Revenue of $13.6M
-44.8% on FY 25
$2.4M
2H 26CASH
BURN/MONTH
-27.7% ON 1H 26
31 March 2026 $7.8M Cash
and cash equivalents
3
-64.8%
on $22.1M at Sept 2025
18,783
COMMERCIAL
TESTS -23.8%
on FY 25
24,190
GLOBAL TESTS
2
-16.3%
on FY 25
$11.5M
OPERATING
REVENUE
-47.4% on
FY 25
US Commercial Tests
14,771, -26.5% on FY 25;
APAC Commercial Tests
4,012, -11.9% on FY 25
7
Operating revenue fell due to Medicare non-coverage determination and disruptions caused by the US shift from Detect to Triage, APAC volumes
show steady growth amid growing albeit small volumes from Asian markets
2H 26 cash burn reduced through careful expense management; further phased reductions towards a target monthly average cash burnfor FY 27
of NZ$2.5m vs NZ$2.85m for FY 26
Net losses increased following revenue reductions and ongoing Medicare appeals not accrued
$24m capital raising launched to strengthen our balance sheet to support ongoing operations and growth, position the company for phased
execution post re-coverage
1. FY 26 financial information is taken from management accounts and has not been audited by Pacific Edge's external auditors. Following the audit process, FY 26 financial information in this presentation
may change. Pacific Edge expects to release its audited financial statements for FY 26 on 25 May 2026
2. Total Laboratory Throughput (TLT) including commercial, pre-commercial and clinical studies testing
3. Cash, short-term deposits and term deposits

CORPORATE OVERVIEW
8
* Non-independent Director
1. Structured debt, not including payables, accruals or lease liabilities
CORPORATE SNAPSHOT
PEBNZX Code:
NZX -NZ$0.174
Share Price:
As at 8 May 2026
1,023 millionShares on issue:
NZ$178 million
Market Capitalisation:
At NZ$0.174 per Share
~53%Top 20 Shareholders:
~NZ$5.1 million
Cash at bank:
As at 30 April 2026
~NZ$0.5 million
Debt
1
:
As at 30 April 2026
BOARD AND MANAGEMENT
Simon Flood (Chairman)is an investment and governance leader with
global capital markets experience in London, Hong Kong and Singapore.
He has held senior executive roles with Mercury Asset Management /
Merrill Lynch Investment Managers, Lion Global Investors and AXA
Investment Managers. He now holds governance roles with private and
public institutions, including Chair of Queenstown Airport.
Dr Peter Meintjes (CEO)is an experienced commercial leader in
molecular diagnostics and genomics focused on nascent market
development of disruptive innovations. Prior to joining Pacific Edge, he
was based in Boston in a succession of diagnostic leadership roles,
including Chief Commercial Officer at Eurofins Transplant Genomics and
the CEO at Omixon.
Anna Stove
Tony Barclay
Sarah Park
Anatole Masfen*
Prof. Dr Bryan Williams
Directors
Dr Tamer Aboushwareb –CMO
Zoe O’Donnell –Head of People
Glen Costin –President APAC
Grant Gibson –CFO
Darrell Morgan –COO
Dr Justin Harvey –CTO
Prof. Dr Parry Guilford –CSO
Senior Leadership
Team

CXBLADDER: TESTS TO RULE OUT CANCER OR PRIORITIZE PATIENTS
THE PATIENT CARE PATHWAY
1. RDM: Residual Disease Monitoring
2. TRM: Therapeutic Response Monitoring
3. NMIBC: non-muscle invasive bladder cancer
4. AUA: American Urological Association
Grade A
Evidence rating by the AUA
4
in its
2025 Microhematuria Guideline
>30
Publications demonstrating AV,
CV or CU evidence
>5,000
Urologists that have ordered
Cxbladder
>130,000
Patients that have used
Cxbladder

THE CXBLADDER SUITE
NMIBC
1
SurveillanceHematuria Evaluation
Surveillance PlusMonitorTriage PlusDetectTriage
CxbladderProduct
Alternative to cystoscopy for
NMIBC patients undergoing
surveillance for recurrence.
Currently in development,
showing improved
performance
Alternative to cystoscopy
for NMIBC patients
undergoing surveillance
for recurrence
Risk stratification and
adjunctive use on any
hematuria patient with
improved performance over
Triage and Detect
Adjunctive use with
cystoscopy on hematuria
patients to resolve diagnostic
dilemmas (e.g. equivocal
cystoscopy and atypical
cytology)
Risk stratification of
microhematuria patients to
rule out the majority of those
patients from further workup
for bladder cancer
Product Summary
13 SNVs across 5 genes
2 fusions associated with 1 gene
1 methylation marker
2 control markers
5 RNA biomarkers + patient
tumor history
5 RNA biomarkers + 6 DNA
SNVs from 2 genes (FGFR3/
TERT)
5 RNA biomarkers5RNAbiomarkers + patient clinical
factors
Analytical composition
All Risk Groups
Sn: Not yet published
Sp: Not yet published
NPV: Not yet published
PPV: Not yet published
All risk groups
5,6
Sn: 93%
Sp: N/A
NPV: 97%
PPV: N/A
Hematuria
4
Sn: 93.6%****
Sp: 98.2%***
NPV: 99.4%****
PPV: 74.6%***
Hematuria
3
Sn: 82%**
Sp: 94%*
NPV: 97%**
PPV: 68%*
Hematuria
2
Sn: 95%
Sp: 45%
NPV: 99%
PPV: N/A
Test Performance
As a non-invasive surveillance alternativePrior to cystoscopy / as an adjunct / 3 weeks post cystoscopyPrior to cystoscopy
When is it used?
CPT-PLA code targeted for Dec 2026
Reimbursed on A58917 in Jul 2027

Commercially available in APAC
and under “early access” in US,
pending coverage

Commercially
available?
$1,800 (seeking by crosswalk)$760$1,328
$760$760
Medicare Pricing (USD)
1. NMIBC: non-muscle invasive bladder cancer
2. Kavalieriset al. (2015) A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuriawho have a low
probability of urothelial carcinoma. BMC Urol2015;15:23.
3. O’Sullivan et al. (2012) A multigene urine test for the detection and stratification of bladder cancer in patients presentingwith hematuria. J Urol2012; 188:741–7.
4. Harvey et al. (2025) Analytical Validation of the Cxbladder® Triage Plus Assay for Risk Stratification of HematuriaPatients for Urothelial Carcinoma. Diagnostics. 2025; 15(14):1739. https://doi.org/10.3390/diagnostics15141739
5. Kavalieriset al. (2017) Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinomain a MulticenterStudy. J Urol2017;197:6,1419-1426.
6. Lotan et al. (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017; 1–8.
* When higher 0.23 cut point on test report is used
** When lower 0.12 cut point on test report is used
*** When higher 0.54 cut point on test report is used
**** When lower 0.15 cut point on test report is used
10

•Cxbladderavoids invasive, unnecessary procedures for patients driving down costs for health systems and payers
2
•At scale, Cxbladdercan spare more than 1.5 million patients in the US from cystoscopy and save >US$500/patient
2
•The population in the USA is ageing, with an increasing number of patients requiring urology care
•The number of urologists per person over 65 is falling in the USA (from 23.8/100k to 15.8/100k in 2035
3
) potentially delaying diagnosis
•Medicare reimbursement for cystoscopy has declined from US$204.80 in 2023 to US$172.80 in 2026
4
1. AUA Guidelines cite incidence of bladder cancer in microhematuria risk categories from 0.4-6%. 5% is an example
2. Tyson et al (2024) Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients -PubMed (PMID: 37914255)
3. Nam et al. (2021) Projected US Urology Workforce per Capita, 2020-2060 JAMA Network Open Published Online:November16,2021
4.https://www.cms.gov/medicare/physician-fee-schedule/search
DRIVING ECONOMIC VALUE FOR PATIENTS, HOSPITALS AND PAYERS
CXBLADDER DELIVERS CLINICAL UTILITY, PATIENT SATISFACTION AND ECONOMIC VALUE
Illustration shows incidence of bladder cancer in microhematuria
populations at 5%
1
With Triage Plus, 85% of patients can avoid cystoscopy, 15% receive
cystoscopy to find the same 5 cancer patients
11
CANCER INCIDENCE IN MICROHEMATURIA PATIENTSCYSTOSCOPIES SAFELY AVOIDED USING CXBLADDER
Cystoscopy
No cancer
Cystoscopy
Cancer
No cystoscopy
No cancer
Cystoscopy
Cancer
Cystoscopy
No cancer

DRIVING STRATEGIC VALUE THROUGH PRODUCT INNOVATION
NEXT GENERATION TESTS HAVE SUPERIOR PERFORMANCE AND PRICING
•Cxbladder Triage Plus has been analytically validated and clinically validated for all hematuria patients (micro and gross)
•Triage Plus has provisional patents filed, AV published, CV published, priced at US$1,328/ test, and coverage has been requestedfrom Novitas
•The US$1,328 price strengthens the economics of operating an Account Executive and the future profitability profile of the company
•Triage Plus is being trialed in ‘early access’ and we are seeking to be added to the AUA microhematuria guideline alongside Triage in FY27
•Cxbladder Surveillance Plus tests for recurrent disease in NMIBC
1
patients
•Surveillance Plus is in development and is expected to be analytically validated and clinically validated during FY27
•Surveillance Plus uses DNA markers and ddPCR
4
technology, has completed a ‘Freedom to Operate’ analysis, and provisional patenting is in progress
•Pacific Edge is targeting to submit Surveillance Plus for a CPT-PLA code by 9 December 2026. If that date is achieved, the code would be approved by CMS before 1
April 2027, effective in the CLFS on 1 July 2027 and added to Novitas’ Local Coverage Article A58917 during July 2027
•Pacific Edge currently expects claim-by-claim reimbursement for Surveillance Plus from July 2027 by Novitas at provisional localpricing once the code is added to
A58917, leading to additional US revenue during FY28, while seeking a pricing crosswalk for Surveillance Plus to a US$1,800 ddPCR
4
test.
1. NMIBC is non-muscle invasive bladder cancer
2. RDM: Residual Disease Monitoring
3. TRM: Therapeutic Response Monitoring
4. ddPCR is droplet digital Polymerase Chain Reaction
12

2. COMMERCIAL PATHWAY AND ANTICIPATED MEDICARE RE-
COVERAGE
13

The committee regularly noted the strong clinical evidence supporting Cxbladder
Triage and Triage Plus throughout the call (most notably STRATA and the Kaiser Study)
Strong
clinical
evidence
Panel supported use of validated biomarkers across all hematuria risk groups and
multiple settings: initial evaluation, reflex after inconclusive tests, adjunct to difficult
cystoscopies, repeat use in recurrent cases, and as a non-invasive option
Use across
all risk
categories
Logistical and economic benefits from primary care use were emphasized, including
better access for rural patients, prioritization of high-risk referrals, earlier detection to
avoid more invasive disease, and advancing care for women where hematuria is often
dismissed as a UTI
Logistical
benefits
Strong alignment that Cxbladder tests have robust evidence and clinical utility, with
several experts explicitly appealing for Medicare reimbursement and broad access to
improve standards of care
Improved
standard of
care
Novitas will use panel feedback, evidence and AUA guideline updates to decide on a
new coverage policy, with a draft LCD expected anytime before September 2026, and a
final-effective LCD expected anytime before March 2027
Pathway to
re-coverage
SUMMARY OF NOVITAS CONTRACTOR ADVISORY COMMITTEE –FEBRUARY 2026
EXPERT PANELISTS HIGHLIGHT NEED FOR REVISIONS TO MEDICARE POLICY
CXBLADDER EVIDENCE AS A DRIVER FOR CHANGE
14





Pacific Edge considers that the panel provided a clear endorsement of urine-based biomarkers as
medically reasonable and necessary and IMPORTANTLY, appropriate for Medicare recoverage
1
“The vast majority of patients with
microhematuria in the US are not getting
referred to urologists or any evaluation
whatsoever... the consequence is that
many patients are getting delayed in
diagnosis”
-Prof Yair Lotan, UTSW
“only 13% of patients with high-risk
microhematuria actually underwent
cystoscopy... so that is why a
biomarker could be so appealing”
-Dr Jason Hafron, Michigan Institute of Urology
1. For more information, please refer to Pacific Edge Limited NZX announcement on Monday, 23 February 2026

CY2027CY2026CATALYSTMEDICARE COVERAGE REQUEST
Q4Q3Q2Q1Q4Q3Q2Q1
STRATA Study (May 2024)
AUA Microhematuria Guideline (Feb 2025)
L39365 Reconsideration request (Triage)
March 2025
AV of Triage Plus (Q2 25)
CV of Triage Plus –DRIVE Study (Q4 25)
New LCD request (Triage/Triage Plus)
November 2025
15
ANTICIPATED MEDICARE RE-COVERAGE: ESTIMATED TIMELINES
DRAFT LCD RELEASE AND FINAL COVERAGE TIMELINES ARE AT THE DISCRETION OF NOVITAS
OUTLOOK: THE PATH TO COVERAGE POLICY AND ENDURING REIMBURSEMENT
•Novitas controls the timeline for publishing an LCD; the framework is governed by
the Medicare Program Integrity Manual
•A draft LCD is subject to ‘notice and comment’ for a minimum of 45 days,
including an open public meeting
•After the draft LCD is published, we will seek reimbursement for products covered
by the draft LCD, noting positive language for hematuria patients can be
differentiated from negative language for cancer patients on L39365
•Novitas must respond to all comments when finalizing the draft LCD and may take
a maximum of 365 days from draft publishing to final publishing
1
•The finalized LCD becomes effective 45 days after being published
LCD finalized (estimate)
Novitas publishes draft LCD (estimate)
12-months after estimated draft (assumed worst case)
Contractor Advisory Meeting (CAC) Meeting –February 19, 2026
1. It is also open to Novitas to retire, rather than finalize, the draft LCD. Novitas must publish the final LCD or retire the draft LCD within 365 days after
publishing a draft LCD

US COMMERCIAL PAYERS: MEDICARE POLICY EXPECTED TO UNLOCK VOLUMES
THE US PRIVATE HEALTH INSURANCE MARKET IS A SIGNIFICANT OPPORTUNITY
•Commercial payers are a significant opportunity covering almost four times more lives than
Medicare. Microhematuria patients skew younger with commercial health insurance, thus
represent the majority of the total serviceable market for hematuria evaluation
•Final coverage policy from Medicare expected to unlock revenue from Commercial Payers by
1) removing a key reason to deny, 2) providing language that commercial payers can adopt in
their own policies and 3) leveraging State Biomarker Laws to mandate payment from
commercial payers
•The commercial payer market is highly concentrated among the largest payers, particularly
UnitedHealthcare and the Blue Cross Blue Shield (BCBS) network
•Each insurer has multiple plans creating a complex coverage landscape
•We focus on establishing medical policy directly with payers or through third parties like
Avalon, EviCore, Carelon, Concert Genetics and ECRI
4
•Pacific Edge has already received positive medical policy from Avalon and ECRI
•In March 2026, BCBS North Carolina and BCBS South Carolina adopted Avalon’s policy
•Commercial Policy achievements like BCBS NC and SC are typically considered a higher bar
than Medicare LCD
KAISER PERMANENTE –REAL WORLD CLINICAL AND ECONOMIC VALUE
•KP SoCal
5
has 4.9 million members. The broader Kaiser system has 12.6 million members
•KP SoCal is contracted for Triage and Monitor and implemented electronic ordering through
their HealthConnectEMR; all 15 sites ordering
•Pacific Edge is working with KP to drive volume growth within KP SoCal
•Pacific Edge has recently entered into an agreement with KP Mid-Atlantic (~800,000 members)
for a pilot study with a Triage protocol that mirrors KP SoCal
•The partnership with KP has delivered compelling real-world evidence for Triage (See
Appendix 3); new studies are expected to deliver similar value for Triage Plus
49.7%
24.1%
20.1%
3.3%
2.7%
COMMERCIAL
MEDICARE
MEDICARE ADVANTAGE
VETERANS AFFAIRS
MEDICAID AND MANAGED
MEDICAID
PACIFIC EDGE PAYER MIX (1H 26)
1. https://www.census.gov/library/publications/2025/demo/p60-288.html
2. https://www.medicare.gov/about-us
3.https://content.naic.org/sites/default/files/2024-annual-health-industry-commentary.pdf
4. ECRI is the Emergency Care Research Institute
5. KP SoCal means the Southern California Permanente Medical Group
~1,200
US private health
insurance payers
3
66m
Medicare
insured lives
2
223m
US private
insured lives
1
16

FY 26 TOTAL LAB THROUGHPUT (TLT*)
•Global TLT of 24,190 for FY 26down 16.3% on FY 25after Medicare
non-coverage determination, reduced reach of the sales force and
the US transition from Detect to Triage for hematuriaevaluation
•APAC volumes showing steady increases with growing volumes ex-NZ
•Global Commercial test volumes of 18,783 for FY 26 down 23.8%
•Triage growing in share of volume validating risk stratification value
proposition and investment in Triage Plus
FY 26 VOLUMES FALL DESPITE MEDICARE POLICY MOMENTUM
TEST VOLUMES BY TYPE (TLT*)
GLOBAL COMMERCIAL TEST VOLUMESGLOBAL TOTAL TEST VOLUMES (TLT*)
*TLT is the Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
17
1H
2H
1H
2H
30%
56%
70%70%
66%
53%
26%
10%
10%
16%
0%
2%
5%
6%
6%
18%
16%
15%
14%
12%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Q4 25Q1 26Q2 26Q3 26Q4 26
PRODUCT MIX (%)
TriageDetectTriage PlusMonitor
14,920
18,240
14,225
13,173
16,645
14,393
14,669
11,017
31,565
32,633
28,894
24,190
-
5,000
10,000
15,000
20,000
25,000
30,000
35,000
FY 23FY 24FY 25FY 26
TESTS
12,422
15,401
12,325
10,371
14,269
11,946
12,317
8,412
26,691
27,347
24,642
18,783
-
5,000
10,000
15,000
20,000
25,000
30,000
FY 23FY 24FY 25FY 26
TESTS

MOUNTING POLICY MOMENTUM YET TO LIFT US VOLUMES
18
SALES FORCE EFFICIENCY LAYS FOUNDATIONS FOR GROWTH
•US operations have faced numerous challenges in FY 26:
•Constant headwind of selling a product not covered by Medicare
•Disruption of transitioning US customers from Cxbladder Detect to Triage after
non-coverage LCD in February 2025
•Winter storms across large segments of the US reducing operating days in Q4 26
•Sales force efficiency metric rises with focus on profitable territories
•8 FTEs in Q4 26 vs 12 FTEs in Q3 26 and peak 33 in Q3 23
•Sales force efficiency metric increased to 530 from 335 in Q3 26 lifted by a focus
on the most profitable territories
•Tests per unique ordering clinician were 5.4 up from 4.8 in Q3 26
•Ordering clinicians fell to 747 from 834 ordering clinicians in Q3 26
US TOTAL LABORATORY THROUGHPUT
US SALES FORCE EFFICIENCY
US CLINICAL COMMITMENT
964
992
978
1,040
1,032
942
834
747
6.1
5.7
5.9
6.2
5.5
5.3
4.8
5.4
-
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
-150
50
250
450
650
850
1,050
1,250
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26
TESTS
US ORDERING CLINICIANS
US ORDERING CLINICIANS (LHS) TESTS/ORDERING CLINICIAN (RHS)
30.0
27.7
20.7
16.0
14.7
15.0
15.3
16.0
15.0
12.3
12.0
7.7
288
265
292
381
403
379 379
406
381
403
335
530
200
250
300
350
400
450
500
550
-
5
10
15
20
25
30
35
Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26
AVERAGE US TEST VOLUME/SALES FTE
AVERAGE SALES FTE
US AVERAGE SALES FTE (LHS)US TEST VOLUME/SALES FTE (RHS)
Light shade: Clinical study and evaluation tests
Dark Shade:Commercial tests
13,550
9,956
9,913
10,177
8,386
6,385
2,412
2,184
1,674
2,121
2,309
1,704
15,962
12,140
11,587
12,298
10,695
8,089
-
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
1H 242H 241H 252H 251H 262H 26
TEST VOLUMES

CONSOLIDATING NEW ZEALAND AND DEVELOPING AUSTRALIA AND SEA
APAC COMMERCIAL
•APAC Commercial and Clinical Operations (excluding R&D costs) is
trending towards profitability (on a direct cost basis) with an FY 26cash
burn rate of $0.6m,a ~40% improvement on the FY 25 year
•APAC revenue contributed 19% of operating revenue in 2H 26, an
increase from 8% in FY 25
•Re-pricing in 2025 created on average 25% more revenue per test
•Wider adoption of Triage Plus over legacy products has the potential
for 20% more revenue growth from the same testing volume, with
testing volume also expected to continue to increase
NEW ZEALAND: SEEKING A NATIONAL HEMATURIA EVALUATION PATHWAY
•~70% of New Zealanders have access to Cxbladdertesting
•Pacific Edge is establishing healthcare equity for all New Zealanders
with a national pathway for hematuria evaluation with TeWhatu Ora
AUSTRALIA: BUSINESS DEVELOPMENT WITH HOSPITAL CONTRACTING
•In Australia we are focused on contracting with individual hospitals that
have evaluated Cxbladder
•Northern Hospital and Townsville have established clinical pathways for
Cxbladderproducts
•MSAC
2
reimbursement requires Cxbladdertests to be run in Australia
•When developed, kit-based IVDs for Cxbladdercan be run by
partner labs in Australia
19
1. Total Laboratory Throughput in Asia and Pacific including commercial, pre-commercial and clinical studies testing
2. MSAC: Medical Services Advisory Committee: advises on public funding for health services for Australian Medicare reimbursement
SOUTHEAST ASIA: BUSINESS DEVELOPMENT WITH EARLY WINS
•In Southeast Asia we are establishing a network of lab partners for
in-market promotion of our testing services
•We have processed commercial samples from seven markets, selling
either directly or through a distributor/lab partner
•Singapore General Hospital implemented the first clinical pathway
for Cxbladder products in March 2026
•Longer-term strategy involves deploying kit-based IVDs through the
lab partner network
APAC TOTAL TEST VOLUME
1
1,851
1,990
2,412
2,140
1,985
2,027
427
263
226
231
493
901
2,278
2,253
2,638
2,371
2,478
2,928
-
500
1,000
1,500
2,000
2,500
3,000
1H 242H 241H 252H 251H 262H 26
TEST VOLUMES
Light shade: Clinical study and evaluation tests
Dark Shade:Commercial tests

3. OUTLOOK
20

OUTLOOK
POSITIONED TO UNLOCK VALUE THROUGH UPCOMING COMMERCIAL, CLINICAL AND INNOVATION MILESTONES
1. Savage et al., Accepted October 6, 2025. Diagnostic Performance of Cxbladder® Triage Plus for the Identification and Stratification of
Patients at Risk for Urothelial Carcinoma: The Multicenter, Prospective, Observational DRIVE Study.
2. ECRI is the Emergency Care Research Institute
INNOVATION DRIVES LONG-TERM
VALUE CREATION
CLINICAL EVIDENCE DRIVES
MEDIUM-TERM VALUE CREATION
COMMERCIAL CATALYSTS FOR NEAR-
TERM VALUE CREATION
•Draft Local Coverage Determination (LCD) for
hematuria evaluation, that includes coverage
for Triage and potentially Triage Plus is currently
expected anytime before September 2026
•Seeking claim-by-claim reimbursement for
hematuria testing after draft coverage, noting
draft policy language may differentiate
hematuria from cancer
•Expert CAC panel gave clear endorsement of
urine-based biomarkers as medically reasonable
and necessary, citing Cxbladder clinical evidence
•Advancing medical policy for Triage with
commercial payers, leveraging the AUA
Guideline, ECRI
2
review and Avalon policy
•Cxbladder is under consideration by Health New
Zealand for a National Pathway in FY 27
•DRIVE publication
1
supports Triage Plus validity;
submitted to Novitasand AUA for coverage and
guideline inclusion
•Kaiser Permanente study shows real world
evidence for CxbladderTriage in largest urine-
based biomarker study of hematuria patients
•Four-year evidence generation program delivers
stepwise milestones for sustained shareholder
value
•AUA (Grade A Evidence), ECRI
2
(4/5 Evidence)
and Avalon (Covered) have created the
precedent for turning Cxbladderevidence into
robust medical policy
•BCBS NC & SC commercial payers have adopted
coverage policy for Triage based on Avalon’s
assessments
•Next generation products demonstrate superior
performance that underpins better clinical
performance, patient experience, healthcare
system cost savings and is expected to
substantially improve unit economics
•TriageௗPlus progressing through ‘early access’;
included in CAC meeting with US$1,328 price —
Medicare coverage is the final step
•Targeting CPT-PLA coding submission for
SurveillanceௗPlus in December, 2026 with claim-
by-claim revenue expected after July 1, 2027
•Seeking claim-by-claim reimbursement at
US$1,800 with provisional pricing at Novitas;
seeking US$1,800 crosswalk price during FY 28
•Ongoing investment in product simplification
and kitted IVD products to enable de-centralized
international deployment
21

4. CAPITAL RAISING OVERVIEW
22

Pacific Edge is undertaking an equity raise of NZ$24 million by way of the offer of new shares, comprising:
A NZ$18 million Placement; and
A NZ$6 million Retail Offer
Proceeds from the Offer will provide capital to:
strengthen the balance sheet to support ongoing operations and position for future growth
support the company to achieve Medicare re-coverage
continue evidence generation
continue product development and innovation
New Shares under the Placement will be issued under Pacific Edge’s 15% placement capacity under NZX Listing Rule 4.5
Transaction
Overview
The Offer will be conducted at a fixed price of NZ$0.170 per share (Offer Price), representing a:
o2.3% discount to the Company’s last traded price on NZX on 8 May 2026;
o2.0% discount to the Company’s 5-day VWAP on NZX (NZ$0.1735)
1
; and
o4.9% discount to the Company’s 30-day VWAP on NZX (NZ$0.1788)
2
Offer Price
Pacific Edge is offering up to NZ$6 million of shares (with the ability to scale applications or accept oversubscriptions at theBoard’s discretion) to Pacific Edge’s
eligible shareholders resident in New Zealand (up to a maximum of NZ$50,000 per shareholder) under a Retail Offer, structuredasa share purchase plan
3
The Retail Offer price will be NZ$0.170 per share
Retail Offer details
Pacific Edge’s Chair, Simon Flood, intends to apply for NZ$500,000 of shares under the Placement
All other Pacific Edge Directors also intend to participate in the Offer
Commitments
New Shares to be issued under both the Placement and Retail Offer will be fully paid shares which, on allotment, will rank equally in all respects with Pacific
Edge’s existing fully paid ordinary shares on issue
Ranking
Refer to Section 5 for a summary of key risks associated with an investment in Pacific Edge and the OfferRisks
Neither the Placement nor the Retail Offer are underwrittenUnderwriting
CAPITAL RAISING OVERVIEW
1. Volume weighted average price on NZX for the period 4 May 2026 to 8 May 2026 (dates inclusive)
2. Volume weighted average price on NZX for the period 25 March 2026 to 8 May 2026 (dates inclusive)
3. Pacific Edge intends to use its placement capacity under NZX Listing Rule 4.5 to ensure that eligible shareholders resident in New Zealand can each subscribe for up to NZ$50,000 in new
shares, even though some shareholders subscribed for shares under the previous share purchase plan undertaken within the last12months
23

TIMETABLE
(NZ time)Placement
Monday, 11 to Tuesday, 12 May 2026Placement conducted under trading halt on the NZX and ASX
Wednesday, 13 May 2026Announcement of the Placement results and trading halt lifted on the NZX and ASX
Friday, 15 May 2026Settlement on the NZX
Friday, 15 May 2026Settlement on the ASX (if required)
Friday, 15 May 2026Allotment and commencement of trading of Placement shares on NZX and ASX
Retail Offer
7:00pm on Friday, 8 May 2026Record date
Thursday, 14 May 2026Retail Offer opens and documentation sent to eligible shareholders
5:00pm on Thursday, 28 May 2026Retail Offer closes
Wednesday, 3 June 2026Announcement of results of Retail Offer
Thursday, 4 June 2026Settlement, allotment and commencement of trading of Retail Offer shares on NZX
24

5. KEY RISKS
25

KEY RISKS
IMPORTANT:
Like any investment, there are risks associated with an investment in Pacific Edge shares. Before investing in Pacific Edge, youshould be aware than an investment in Pacific
Edge has a number of risks, some of which are specific to Pacific Edge and some of which relate to listed securities generally, and many of which are beyond the control of
Pacific Edge. Additionally, some risks may be unknown and other risks, currently believed to be immaterial, could turn out tobematerial. Whilst the section below aims to
highlight some of the key risks, it is not exhaustive.
Pacific Edge is a growth company that is currently making losses and it may need to raise more capital in the future, which may or may not be available at the time. Pacific
Edge is currently assuming it will receive a positive draft LCD outcome anytime before September 2026 to regain Medicare re-coverage, which may or may not ultimately
eventuate in the time envisaged, or at all. An investment in Pacific Edge is not for all investors and there is a risk you could lose all of your money.
Before deciding whether to invest in Pacific Edge shares, you must make your own assessment of the risks associated with the investment and consider whether such an
investment is suitable for you having regard to all other Pacific Edge continuous disclosure announcements, financial statementsand other publicly available information.
This presentation is not a prospectus or a product disclosure statement or other offering document. It has been prepared withouttaking in account the objectives, financial
situation or circumstances of investors. It may not contain all the information you require to make an investment decision. Accordingly, before making an investment
decision, you should consult your financial adviser and other professional advisers.
26

KEY RISKS (CONTINUED)
Pacific Edge currently has a Medicare non-coverage determination for Triage, Triage Plus, Detect and Monitor, and no coverage determination for Surveillance Plus. Medicare
previously accounted for the majority of Pacific Edge’s US test volumes and, therefore, a significant percentage of Pacific Edge's revenue. Although Pacific Edge is confident that it
will regain coverage for Triage and potentially gain coverage for Triage Plus as a result of recent AUA guideline inclusion, newclinical evidence and the Contractor Advisory
Committee (CAC) meeting held on 19 February 2026 (US time), there are no guarantees as to the timing or outcome of the re-coverage process, because these timelines are
controlled by Novitas. Novitas has 12 months from the date of publishing the draft LCD to finalize or retire it, meaning Medicare coverage could still take some time or not be
achieved at all. If the language is changed between the draft and the final version to non-cover or reduce coverage for Cxbladder Triage or Triage Plus, this would have a material
adverse impact on Pacific Edge's financial performance and growth, and could result in the company using up all available cash before it is able to become profitable from its
ongoing operations.
If the final-effective LCD does not cover Cxbladder Triage and Triage Plus, Pacific Edge will likely need to complete further clinical studies to provide new published evidence when
submitting another reconsideration request. Those clinical studies are underway, but may take a number of years to complete. Accordingly, Pacific Edge may need to undertake a
restructure of its business to reduce costs and, potentially, seek to raise further capital and/or pursue other capital initiatives.
Medicare coverage
uncertainty
Pacific Edge is operating at a 'cash burn', which means that the company spends more cash that it generates. The capital raise outlined in this presentation is in part to provide
sufficient cash to regain Medicare coverage. If the capital raise is undersubscribed, if Medicare re-coverage is not achieved orsignificantly delayed, or is only for Triage and not also
Triage Plus, or the business is impacted adversely by other events, there is a risk to the ongoing financial viability of Pacific Edge, which may result in investors losing some or all of
their investment.
Ongoing Financial
Viability
Pacific Edge’s Cxbladder products and laboratories are regulated and certified by various government and industry entities interritories and markets in which the tests are
performed and/or sold. Reimbursement for these tests may be influenced by reimbursement rulings from private and/or government payers. Guidelines issued by various industry
bodies also influence the treatment and management regimes for patients, with the potential to impact on the uptake and use of Cxbladder. If Pacific Edge is unable to retain or, in
certain markets, gain inclusion in guidelines, or the current regulatory approvals and reimbursement obtained for existing products are removed or reduced, such matters could
have an adverse impact on Pacific Edge’s financial performance and its ability to achieve its business plans. If Pacific Edgeisunable to obtain the approvals required for new
products in new territories, or is unable to obtain future reimbursement for new products, this could also have an adverse impact on Pacific Edge’s financial performance and its
ability to achieve its business plans.
Regulatory, industry
body and guideline
Risks
The global cancer diagnostics industry is highly competitive, with research undertaken by a large number of commercial and not for profit institutions globally on new diagnostic
tools. There are some smaller companies with minimal clinical evidence to support their use, or with no commercial presence in the USA, but there are also a large number of well
capitalized diagnostics companies operating in the broader industry. There is a risk that the larger, better capitalized companies may discover, develop or introduce new products
that compete with Pacific Edge’s products, and if successful, could render Pacific Edge’s products obsolete or otherwise uncompetitive, resulting in adverse effects on Pacific Edge’s
revenue, margins and profitability.
Competition
27

KEY RISKS (CONTINUED)
Pacific Edge relies on laboratory operations, third party suppliers of test components, IT and technical systems to process and report results for Cxbladder tests. While the
performance of Cxbladder has been demonstrated in various scientific journal publications, any change to the reliability, repeatability, reproducibility or accuracy of Cxbladder
products and technology systems has the potential to impact Pacific Edge’s business and reputation. Cyber attacks on PacificEdge digital systems and platforms also have the
potential to impact the delivery of test results. Financial, reputational and litigation consequences relating to underperformance and unreliability, or the inability to deliver, test
results (including due to adverse cyber incidents or quality issues with test components supplied by third parties) have the potential to be significant and could be materially adverse
to the company's financial performance and position.
Product and
technology risk
Pacific Edge continues to leverage its suite of patents and intellectual property to explore new products and applications. There is a risk that those development efforts may not be
successful or may take longer and be more expensive than anticipated, and as a result, Pacific Edge’s investment will be delayedor lost. This risk could arise due to a number of
factors, including delays in commencement or completion of scientific studies. Any failure or significant delay in the development of one or more of Pacific Edge’s new products
and product extensions may have a material negative impact on Pacific Edge’s financial performance and growth.
New Product
Development
In the ordinary course of conducting its business, Pacific Edge is exposed to potential litigation and other proceedings, including through claims of intellectual property infringement
or breach of agreements. If such proceedings are brought against Pacific Edge, Pacific Edge could incur considerable defencecosts (even if successful), with the potential for
damages and costs awards against Pacific Edge if it were unsuccessful, which could have a significant adverse financial impact on Pacific Edge.
Circumstances may also arise in which Pacific Edge considers that it is reasonable or necessary to initiate litigation or other proceedings, including for example to protect its
intellectual property rights.
Litigation
The success of our business depends significantly on the continued contributions of our executive team, scientific leaders, and key technical staff. The unexpected departure of any
of these individuals could disrupt operations, delay research and development efforts, and negatively impact strategic initiatives. Attracting and retaining top talent in a competitive
biotech labor market remains a critical challenge.
Key Person Risk
Any investment in equity capital markets carries general risks. Pacific Edge’s shares are currently listed on NZX and the ASX, and are subject to the usual market-related forces which
impact on Pacific Edge’s share price. There can be no assurance that trading in the shares following the offer will be at a price at or above the price paid by investors in the offer. The
equity markets can be subject to pronounced volatility. This volatility could have a materially adverse impact on the market price of Pacific Edge shares.
Factors such as the risk factors disclosed in this presentation as well as other factors could cause the market price of PacificEdge’s shares to decline or to materially fluctuate. It also
is possible that new market risks may develop as a result of the New Zealand or Australian markets experiencing extreme stress, or due to existing risks manifesting themselves in
ways that are not currently foreseeable. A weakening in the New Zealand or Australian dollar as against other currencies may cause the value of the shares to decline in any
portfolio which is denominated in a currency other than New Zealand dollars.
Market volatility of
Pacific Edge’s shares
Pacific Edge’s operating and financial performance is influenced by a variety of general economic and business conditions in NewZealand, the United States, Southeast Asia and
globally. A prolonged deterioration in general economic conditions, which may lead to a decrease or reprioritisationof healthcare spending, has the potential to have a material
adverse effect on Pacific Edge’s business or financial condition (or both). In addition, uncertain and dynamic geopolitical risks, including international conflicts, sanctions, tariffs and
political instability may disrupt Pacific Edge’s supply chains and access to, or costs to operate in, certain markets. Any ofthese may have an adverse effect on Pacific Edge’s business
or financial performance (or both).
General economic
conditions
28

6. FOREIGN SELLING RESTRICTIONS
29

FOREIGN SELLING RESTRICTIONS
Offer Selling Restrictions
This document does not constitute an offer of new ordinary shares ("New Shares")of Pacific Edge in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person,
and the New Shares, may not be offered or sold in any country except to the extent permitted below.
Australia
This document and the offer of New Shares are only made available in Australia to persons to whom an offer of securities can be made without disclosure in accordance with applicable exemptions in sections 761G
(wholesale clients), 708(8) (sophisticated investors), 708(10) (experienced investors) and 708(11) (professional investors) of the Australian Corporations Act 2001 (Cth) (the "Corporations Act"). This document is not
a prospectus, product disclosure statement or any other formal "disclosure document" for the purposes of Australian law and is not required to, and does not, contain all the information which would be required in
a "disclosure document" under Australian law. This document has not been and will not be lodged or registered with the Australian Securities & Investments Commission. Prospective investors should not construe
anything in this document as legal, business or tax advice nor as financial product advice for the purposes of Chapter 7 of the Corporations Act and the information provided does not take into account the
investment objectives, financial situation or particular needs (including financial and tax issues) of any prospective investor.Prospective investors should review the risks set out on slides 26 to 28 before making any
investment decision.
30

FOREIGN SELLING RESTRICTIONS (CONTINUED)
Hong Kong
WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it beenauthorisedby
the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws ofHong Kong (the "SFO"). Accordingly, this document may not be distributed, and the
New Shares may not be offered or sold, in Hong Kong other than to “professional investors” (as defined in the SFO and any rules made under that ordinance).
No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in thepossession of any person for the purpose of issue, in Hong Kong or elsewhere that is
directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that
are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allottedNew Shares may sell, or offer to sell, such securities in circumstances that amount to an
offer to the public in Hong Kong within six months following the date of issue of such securities.
The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document,
you should obtain independent professional advice.
Singapore
This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this
document and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares
be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision
(4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the “SFA”) or another exemption under the SFA.
This document has been given to you on the basis that you arean “institutional investor” or an “accredited investor” (as such terms are defined in the SFA). If you are not such an investor, please return this
document immediately. You may not forward or circulate this document to any other person in Singapore.
Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singaporemay be applicable to investors who acquire New
Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.
United States
This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or
the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold in the United States except in transactions exempt from, or not subject to, the
registration requirements of the US Securities Act and applicable US state securities laws. New Shares will not be offered inthe United States.
31

7. APPENDICES
APPENDIX 1: Global Market Opportunity
32

BLADDER CANCER –A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE
33
INCIDENCE PER 100,000 OF THE POPULATION
<1.7 1.7 to 2.7 2.7 to 5.3 5.3 to 8.6 >8.6
1. Sievert et al (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009 Mar 7;27(3):295–300. doi: 10.1007/s00345-009-0395-z
2. World Cancer Research Fund. Statistics are from 2022.
3. Average recurrence for low grade non-muscle invasive bladder cancer as published in Palou J et al (2012): EurUrol2012; 62: 118.
4. Pacific Edge estimate for Global Total Addressable Market (TAM) using US$1,328 price for hematuria testing (priced by Medicare) and US$1800 for NMIBC surveillance (seeking
crosswalk price –not yet priced by Medicare) with next generation products Triage Plus and Surveillance Plus. Other market assumptions for APAC and Europe. See slide 43 for details.
9
th
Most common
cancer world-
wide
2
6
th
Most common
cancer in men
2
1st
Costliest cancer to
treat on a per-
patient basis
1
>50%
Recurrence
3
>220K
Annual
Deaths
2
~614K
Annual cases
and growing
2
US$10.8b
4
Global Market Opportunity

US$10.8b
Global TAM
1
CXBLADDER MARKET OPPORTUNITY
CXBLADDER OFFERS A SIGNIFICANT ADDRESSABLE GLOBAL MARKET ANNUALLY
~7m~3.5m~1.1m~90k ~750kUS$6.7b340m
~17m~8.5m~3.3m~58k~300kUS$2.1b830m
~12m~6m>4.0m ~180k~1mUS$2.0b600m
APAC
Primary growth
focus due to higher
CMS pricing
NZ market mature.
Australia and SEA in
business development
New market accessed
via IVD / kitted tests
1. Pacific Edge estimate using US$1,328 price for hematuria testing (priced by Medicare) in the US and US$1,800 for NMIBC surveillance (seeking crosswalk price –not yet priced by Medicare) with next
generation products Triage Plus and Surveillance Plus. Other market assumptions for APAC and Europe. See slide 42 for details.
2. RDM: Residual Disease Monitoring
3. TRM: Therapeutic Response Monitoring
Present with
hematuria
Referred for
clinical workup
Receive
cystoscopy
Annual cases of
bladder cancer
Living with bladder cancerTAMPopulation
SURVEILLANCE
(RDM
2
, TRM
3
, RECURRENCE)
PATIENT/DISEASE MANAGEMENT
(CLINICAL DECISION MAKING)
34

APPENDIX 2: Financial Performance
35

POSITIONING PACIFIC EDGE FOR MEDICARE RE-COVERAGE
COST SAVINGS MINIMIZE CASH BURN
•Operating revenue fell after loss of
Medicare and Medicare Advantage
coverage and reduced test volumes
•We have not accrued revenue from
Medicare tests during FY 26 while we
pursue the appeals strategy
•We continue to maintain a US market
presence that positions the company for
regaining Medicare coverage, while
focusing on reducing operating expenses,
which fell 12.2% in 2H 26 against 1H 26
•Sales force reductions and other capital
saving measures have cycled through from
1H 26 into 2H 26, with 2H 26 monthly cash
burn 27.7% lower than 1H 26
•Secured $20.7 million in new equity in
August 2025
1. FY 26 financial information is taken from management accounts and has not been audited by Pacific Edge's external auditors. Following the audit process, FY 26 financial
information in this presentation may change. Pacific Edge expects to release its audited financial statements for FY 26 on 25May 2026
2. Net cash, cash equivalents and short-term deposits at the end of the period
36
FY 26 vs
FY 25
2H 26 vs
1H 26
FY 25
(Audited)
FY 26
1
(Draft)
1H 26
1
2H 26
1
(Draft)
Financial Period ($000)
1
(47.4%)(6.4%)$21,846$11,499$5,939$5,560Operating Revenue
(44.8%)(9.4%)$24,616$13,579$7,123$6,456Total Revenue
(9.7%)(12.2%)$54,552$49,279$26,239$23,040Operating Expenses
19.3%(13.2%)($29,936)($35,700)($19,116)($16,584)Net Loss After Tax
(38.7%)(34.3%)$21,572$13,230$7,985$5,245Cash Receipts from Customers
29.1%(32.1%)($24,740)($31,938)($19,026)($12,912)Net Cash Flows to Operating Activities
(65.5%)(64.8%)$22,568$7,776$22,121$7,776Net Cash
2
23.4%(27.7%)$2.3$2.8$3.3$2.4Monthly Cash Burn (NZ$m)

APPENDIX 3: Clinical Studies
37

38
•Pacific Edge generates clinical evidence required
to drive behavior change in physicians
•Clinical evidence is generated within a framework
of Analytical Validity (AV), Clinical Validity (CV)
and Clinical Utility (CU)
•Clinical Studies have clearly defined patient
populations with the endpoints and sample sizes
required for coverage decisions and guideline
inclusion
•We are seeking Medicare coverage for Triage,
Monitor and Triage Plus through reconsideration
requests to Novitas based on new evidence
DRIVING CLINICAL VALUE FOR PHYSICIANS, HOSPITALS AND PAYERS
COMPELLING CLINICAL EVIDENCE CHANGES CLINICAL PRACTICE, MEDICAL POLICY AND GUIDELINES
PUBLICATION DATE
(1)
TEST AND EVIDENCESTUDY
Published May 2024
-CU of Triage
1. STRATA Clinical Utility
Published September 2024
-AV of Triage, Detect and Monitor
2. Automated RNA & DNA extraction
Published July 2025
-AV of Triage Plus
3. Triage Plus Analytical Validation
Published October 2025
7
-CV of Triage Plus
4. DRIVE Clinical Validation
Q3 2026
-CU of Triage Plus (concordance
2
)
5. STRATA second publication
Q3 2026
-CVof Triage Plus
6. AUSSIE Clinical Validation
Q12027
-CV of Triage Plus
7. microDRIVEClinical Validation
Q2 2027
-AV of Surveillance Plus
8. Surveillance Plus Analytical Validation
Q1 2027
-CV of Triage Plus
9. Pooled Analysis MH Clinical Validation
3
Q1 2027
-CV of Triage Plus
10. Pooled Analysis GH Clinical Validation
3
Q2 2027
-CV of Monitor/SurveillancePlus
11. LOBSTER Clinical Validation
Q1 2028
-CU of Triage Plus
12. CREDIBLE Clinical Utility
Q2 2028
-CU Surveillance Plus
13. OCTOPUS Clinical Utility
1
All dates are calendar year and our best current estimates
2
Concordance will be demonstrated by comparing Triage and Triage Plus on identical samples
3
The MH and GH pooled analysis brings together data from DRIVE, AUSSIE and microDRIVE
Already published evidence

INDEPENDENT STUDIES SUPPLEMENT OUR EVIDENCE PORTFOLIO
INVESTIGATOR INITIATED TRIALS AND INDEPENDENT STUDIES DELIVER CLINICAL UTILITY AT MODEST SCALE
LARGEST EVER CLINICAL STUDY OF URINE-BASED
BIOMARKERS FOR HEMATURIA EVALUATION
1. All dates are calendar year and our best current estimates
2. Filson et al (2026); Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study, Urology Practice® (2026), doi: 10.1097/UPJ.0000000000000972.
3. BCG: Bacillus Calmette–Guérin is a bacterium instilled into the bladder that triggers an immune response that targets and destroys cancer cells.
4. MIBC: Muscle Invasive Bladder Cancer
PUBLICATION DATE
1
TEST AND EVIDENCE TYPEINSTITUTIONINDEPENDENT STUDY FOCUS
Q1 2026
2
CU Triage (RWE)Kaiser
Permanente, US
Real World Utility of Triage in MH: A
Matched Cohort Study
Q2 2026CU MonitorMayo Clinic, USPatient preference and satisfaction of
“biomarkers vs cystoscopy”
Q3 2026CU of Triage PlusCanterbury DHBNZ Hematuria Pathway comparing T/D
with Triage Plus on AUSSIE samples
2027CU Triage PlusKaiser
Permanente, US
Retrospective concordance of Triage
and Triage Plus in the Kaiser System
2027CU Triage Plus UT Southwestern,
US
Test utility in screening patients at risk
for bladder cancer
2027CU Monitor
CU Surveillance Plus
Israel Institute of
Technology, Israel
Test utility in assessing therapy success
in a reduced chemotherapy protocol for
upper tract tumors
2027
CU Monitor
CU Surveillance Plus
University of
Miami, US
Test utility in assessing response to
BCG
3
in high-grade bladder cancer
patients
2028
CU Monitor
CU Surveillance Plus
Cleveland Clinic,
US
Test utility for the surveillance of MIBC
4
treated with bladder sparing methods
(PRESERVE Trial)
2029
CU Monitor
CU Surveillance Plus
National Institutes
of Health, US
A Randomized Trial of Apalutamide in
Non-Muscle Invasive Bladder Cancer
Already published evidence
risk-matched patients for
indisputable statistical power
3,353
of patients identified as low
probability by Cxbladder Triage
~80%
cystoscopies avoided (284 per
1,000 referrals for hematuria) & 70
CTs avoided (21 per 1,000 referrals)
952
No difference in overall cancer detection rates
between those who received the Triage test (0.33%)
and their matched cohort (0.6%) (p=0.105)
39

202820272026202520242023
Pre
2023
Calendar year
Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1
STRATA
DRIVE
AUSSIE
microDRIVE
Pooled CV
CREDIBLE
HEMATURIA EVALUATION FIVE YEAR CLINICAL STUDIES ROADMAP
*
*
*
*
*
Publication Submitted
Records review / follow-up
Database lock
Legend:
Pre-activation (docs, CTA etc)
SIV
Enrollment
Data Cleaning
*
DBL
DBL
DBL
40

202820272026202520242023
Pre
2023
Calendar year
Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1
“The 1800”
1
LOBSTER
OCTOPUS
*
SURVEILLANCE FIVE YEAR CLINICAL STUDIES ROADMAP
41
Publication Submitted
Records review / follow-up
Database lock
Legend:
Pre-activation (docs, CTA etc)
SIV
Enrollment
Data Cleaning
*
DBL
Scheduled surveillance visits
CAB
2
*
1. “The 1800” is the Surveillance Plus development dataset
2. CAB is the Pacific Edge Clinical Advisory Board. It was convened at SUO in Arizona to review and confirm the clinical study trial design for OCTOPUS

SOURCES AND ASSUMPTIONS -TOTAL ADDRESSABLE MARKET
42

FOR MORE INFORMATION:
Dr. Peter Meintjes
Chief Executive Officer
email: peter.meintjes@pelnz.com
Grant Gibson
Chief Financial Officer
email: grant.gibson@pelnz.com
Pacific Edge
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 577 6733 Within NZ 0800 555 563
email: investors@pacificedge.co.nz
www.pacificedgedx.com
43

---

Corporate Action Notice
(Other than for a Distribution)
Updated January 2024
Page 1 of 3
Section 1: Issuer information (mandatory)
Name of issuer Pacific Edge Limited
Class of Financial ProductOrdinary shares
NZX ticker codePEB
ISIN (If unknown, check on NZX
website)
NZPEBE0002S1
Name of RegistryMUFG Pension & Market Services
Share Purchase
Plan/retail offer
XRenounceable
Rights issue or
Accelerated
Offer
Capital
reconstruction
Non-
Renounceable
Rights issue or
Accelerated
Offer
CallBonus issue
Type of corporate action
(Please mark with an X in the relevant
box/es)
PlacementX
Record Date 08/05/2026
Ex Date (one business day before the
Record Date)
07/05/2026
CurrencyNZD
External approvals required before offer
can proceed on an unconditional basis?
No
Details of approvals requiredN/A
Section 6: Share Purchase Plans/retail offer
Number of Equity Securities to be
issued
OR
Maximum dollar amount of Equity
Securities to be issued
Up to NZ$6 million of new fully paid ordinary shares
(subject to the ability for PEB to scale applications or
accept oversubscriptions at its complete discretion).
Minimum application amount (if any)$100
Maximum application amount per
Equity Security holder
NZ$50,000 per eligible New Zealand shareholder (or
per eligible New Zealand beneficial owner, in the case
of holdings held by custodians). Any amount issued to
such eligible shareholder / eligible beneficial owner in
excess of the prescribed limit under NZX Listing Rule

2 of 3
4.3.1(c) of NZ$50,000 per shareholder under all of
PEB’s share purchase plans in the prior 12-month
period will be undertaken using PEB’s placement
capacity under NZX Listing Rule 4.5.1.
Subscription price per Equity SecurityNZ$0.170 per ordinary share.
Scaling reference date
1
The Record Date.
Closing date28/05/2026
Allotment date04/06/2026
Section 7: Placement
Number of Equity Securities to be
issued
Up to 105,882,352 new fully paid ordinary shares
(subject to the ability for PEB to accept
oversubscriptions at its complete discretion).
Issue price per Equity SecurityNZ$0.170 per ordinary share.
Maximum dollar amount of Equity
Securities to be issued
NZ$18 million (subject to the ability for PEB to accept
oversubscriptions at its complete discretion).
Proposed issue date15/05/2026
Existing holders eligible to participateYes
Related Parties eligible to participateYes
Basis upon which participation by
existing Equity Security holders will be
determined
By reference to shareholdings at 7.00pm on the
Record Date of 08/05/2026.
It is intended that eligible shareholders who bid for an
amount up to their ‘pro rata’ share of new ordinary
shares under the placement will be allocated their full
bid, on a best efforts basis.
Purpose(s) for which the Issuer is
issuing the Equity Securities
The purpose of the placement is to raise capital to:
•strengthen the balance sheet to support
ongoing operations and position for future
growth;
•support PEB to achieve Medicare re-
coverage;
•continue evidence generation; and
•continue product development and
innovation.
Reason for placement rather than a
pro-rata rights issue or an offer under a
Share Purchase Plan in which the
Issuer’s existing Equity Security holders
would have been eligible to participate
PEB has chosen to undertake a placement in
conjunction with a share purchase plan to raise
capital.
PEB considers this capital raising structure to be in
the best interests of PEB and its existing
shareholders, as:
•compared to other capital raising structures
(such as a pro-rata rights issue), the structure
provides greater certainty around the
1
Scaling for a Share Purchase Plan must be determined as set out in the definition of “Share Purchase Plan” in the Listing Rules.
Retail offers may apply a different basis for scaling.

3 of 3
achievement of the targeted raising size and
more favourable pricing for PEB;
•it is able to be structured to give the vast
majority of PEB’s shareholders the opportunity
to maintain their relative shareholdings if
desired; and
•the structure is well understood by PEB’s
shareholders having been used for PEB’s
most recent capital raising in 2025, which was
considered by PEB to be a successful capital
raise in relation to the amount of capital raised
and the pricing achieved.
Equity Securities to be issued subject to
voluntary escrow
No
Number and class of Equity Securities
to be issued that will be subject to
voluntary escrow and the date from
which they will cease to be escrowed
N/A
Section 8: Lead Manager and Underwriter (mandatory)
Lead Manager(s) appointedNo
Name of Lead Manager(s)N/A
Fees, commission or other
consideration payable to Lead
Manager(s) for acting as lead
manager(s)
N/A
UnderwrittenNo
Name of Underwriter(s)N/A
Extent of underwriting (i.e. amount or
proportion of the offer that is
underwritten)
N/A
Fees, commission or other
consideration payable to Underwriter(s)
for acting as underwriter(s)
N/A
Summary of significant events that
could lead to the underwriting being
terminated
N/A
Section 9: Authority for this announcement (mandatory)
Name of person authorised to make this
announcement
Grant Gibson
Contact person for this announcementGrant Gibson
Contact phone number+64 275 999 943
Contact email addressgrant.gibson@pelnz.com
Date of release through MAP08/05/2026

---

103614.0007 - 2125048
8 May 2026
NZX Limited
Level 1, NZX Centre
11 Cable Street
Wellington 6011
ASX Limited
Level 27, 39 Martin Place
Sydney NSW 2000
NOTICE PURSUANT TO CLAUSE 20(1)(A) OF SCHEDULE 8 TO THE FINANCIAL MARKETS
CONDUCT REGULATIONS 2014 AND PARAGRAPH 708(12J) OF THE CORPORATIONS ACT
2001 (CTH) AS NOTIONALLY INSERTED BY ASIC INSTRUMENT 21-0811
1.Pacific Edge Limited (NZX/ASX: PEB) (“PEB”) intends to undertake an offer of new fully paid ordinary
shares in PEB of the same class as already quoted on the Main Board of NZX Limited and the Australian
Securities Exchange operated by ASX Limited (“New Shares”), comprising:
(a)a non-underwritten placement of New Shares to selected investors to raise up to NZ$18 million;
and
(b)a non-underwritten retail offer to PEB’s eligible existing shareholders with a registered address in
New Zealand to raise up to NZ$6 million (subject to the ability for PEB to scale applications or
accept oversubscriptions at its complete discretion),
(together, the “Offer”).
2.The Offer is being made to investors in New Zealand in reliance upon the exclusion in clause 19 of
Schedule 1 to the Financial Markets Conduct Act 2013.
3.This notice is provided under subclause 20(1)(a) of Schedule 8 to the Financial Markets Conduct
Regulations 2014 (the “Regulations”) and under paragraph 708A(12J) of the Corporations Act 2001 (Cth)
(“Corporations Act”), as notionally inserted by ASIC Instrument 21-0811.
4.PEB will issue the relevant shares under the Offer without disclosure to investors under Part 6D.2 of the
Corporations Act.
5.As at the date of this notice:
(a)PEB is in compliance with the continuous disclosure obligations that apply to it in relation to PEB’s
ordinary shares;
(b)PEB is in compliance with its financial reporting obligations (as defined in subclause 20(5) of
Schedule 8 to the Regulations);
(c)there is no information that is “excluded information” (as defined in subclause 20(5) of Schedule
8 to the Regulations) in respect of PEB; and
(d)PEB has complied with its obligations under Rule 1.15.2 of the listing rules of ASX Limited.
6.The Offer is not expected to have any effect on the control of PEB within the meaning set out in clause 48
of Schedule 1 to the Financial Markets Conduct Act 2013.

103614.0007 - 2125048
Pg. 2
Ends
This notice has been authorised for release to NZX and ASX by the PEB Board.
For further information please contact:
Grant Gibson
Chief Financial Officer
+64 275 999 943

---

Appendix 3B - Proposed issue of securities
Appendix 3B - Proposed issue of securities
1 / 8
Announcement Summary
Entity name
PACIFIC EDGE LIMITED
Announcement Type
New announcement
Date of this announcement
8/5/2026
The Proposed issue is:
Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan
ASX +security code+Security description
Maximum Number of
+securities to be issued
PEBORDINARY FULLY PAID FOREIGN EXEMPT NZX35,294,117
+Record date
8/5/2026
Offer closing date
28/5/2026
+Issue date
4/6/2026
Total number of +securities proposed to be issued for a placement or other type of issue
ASX +security code+Security description
Maximum Number of
+securities to be issued
PEBORDINARY FULLY PAID FOREIGN EXEMPT NZX105,882,352
Proposed +issue date
15/5/2026
Refer to next page for full details of the announcement
A placement or other type of issueA placement or other type of issue
An offer of securities under a securities purchase plan

Appendix 3B - Proposed issue of securities
Appendix 3B - Proposed issue of securities
2 / 8
Part 1 - Entity and announcement details
1.1 Name of +Entity
PACIFIC EDGE LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees
to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in
Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also
apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set
out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under
the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX
an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
1.2 Registered Number Type
ARBN
Registration Number
653308144
1.3 ASX issuer code
PEB
1.4 The announcement is
1.5 Date of this announcement
8/5/2026
1.6 The Proposed issue is:
A placement or other type of issueA placement or other type of issue
An offer of +securities under a +securities purchase plan
New announcement

Appendix 3B - Proposed issue of securities
Appendix 3B - Proposed issue of securities
3 / 8
Part 4 - Details of proposed offer under securities purchase plan
Part 4A - Conditions
4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities
under the +securities purchase plan issue can proceed on an unconditional basis?
No

Appendix 3B - Proposed issue of securities
Appendix 3B - Proposed issue of securities
4 / 8
Part 4B - Offer details
+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities
proposed to be issued
ASX +security code and description
PEB : ORDINARY FULLY PAID FOREIGN EXEMPT NZX
Will the proposed issue of this
+security include an offer of
attaching +securities?
Details of +securities proposed to be issued
ASX +security code and description
PEB : ORDINARY FULLY PAID FOREIGN EXEMPT NZX
Maximum total number of those +securities that could be issued
if all offers under the +securities purchase plan are accepted
35,294,117
Will the offer be conditional on applications for a minimum
number of +securities being received or a minimum amount
being raised (i.e. a minimum subscription condition)?
Will the offer be conditional on applications for a maximum
number of +securities being received or a maximum amount
being raised (i.e. a maximum subscription condition)?
Will individual security holders be required to accept the offer for
a minimum number or value of +securities (i.e. a minimum
acceptance condition)?
Will individual security holders be limited to accepting the offer
for a maximum number or value of +securities (i.e. a maximum
acceptance condition)?
Is the maximum acceptance unit based or dollar based?
Please enter the maximum acceptance value
$ 50,000
Describe all the applicable parcels available for this offer in number of securities or dollar value
Right to subscribe for up to NZ $50,000 in new shares. Applicable parcels to be determined.
Offer price details
Has the offer price been determined?
In what currency will the offer
be made?
What is the offer price per
+security?
Yes
Dollar based ($)
Yes
No
No
No
No
Yes
Dollar based ($)
Yes
No
No
No
No
Yes
Dollar based ($)
Yes
No
No
No
No

Appendix 3B - Proposed issue of securities
Appendix 3B - Proposed issue of securities
5 / 8
be made?
NZD - New Zealand Dollar
+security?
NZD 0.17000
AUD equivalent to Offer Price
amount per +security
0.13940000
FX rate (in format AUD 1.00 /
primary currency rate):
AUD 1.00
FX rate (in format AUD
rate/primary currency rate)
Primary Currency rate
NZD 1.22000000
Oversubscription & Scale back details
Will a scale back be applied if the offer is over-subscribed?
Describe the scale back arrangements
To be determined at the discretion of the Board at the relevant time
Will these +securities rank equally in all respects from their issue date with the existing issued
+securities in that class?
Part 4C - Timetable
4C.1 Date of announcement of +security purchase plan
11/5/2026
4C.2 +Record date
8/5/2026
4C.3 Date on which offer documents will be made available to investors
14/5/2026
4C.4 Offer open date
14/5/2026
4C.5 Offer closing date
28/5/2026
4C.7 +Issue date and last day for entity to announce results of +security
purchase plan offer
4/6/2026
Part 4E - Fees and expenses
4E.1 Will there be a lead manager or broker to the proposed offer?
Yes
Yes
Yes
Yes
Yes
Yes

Appendix 3B - Proposed issue of securities
Appendix 3B - Proposed issue of securities
6 / 8
4E.2 Is the proposed offer to be underwritten?
4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a
handling fee or commission?
4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer
Standard legal, registry costs and corporate advisory fees to Cameron Partners in line with customary levels for
transactions of this nature.
Part 4F - Further Information
4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue
Funds will be used to strengthen the balance sheet to support ongoing operations and growth, support the company to
achieve Medicare re¿coverage, and continue evidence generation, product development and innovation.
4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?
4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer
All jurisdictions except New Zealand
4F.3 URL on the entity's website where investors can download information about the proposed offer
https://www.pacificedgedx.com/
4F.4 Any other information the entity wishes to provide about the proposed offer
No
No
No
No

Appendix 3B - Proposed issue of securities
Appendix 3B - Proposed issue of securities
7 / 8
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other
type of issue can proceed on an unconditional basis?
Part 7B - Issue details
Is the proposed security a 'New
class' (+securities in a class that is
not yet quoted or recorded by ASX)
or an 'Existing class' (additional
securities in a class that is already
quoted or recorded by ASX)?
Will the proposed issue of this
+security include an offer of
attaching +securities?
Details of +securities proposed to be issued
ASX +security code and description
PEB : ORDINARY FULLY PAID FOREIGN EXEMPT NZX
Number of +securities proposed to be issued
105,882,352
Offer price details
Are the +securities proposed to be issued being issued for a cash
consideration?
In what currency is the cash
consideration being paid?
NZD - New Zealand Dollar
What is the issue price per
+security?
NZD 0.17000
AUD equivalent to issue price amount per +security
0.139400
FX rate (in format AUD 1.00 / primary
currency rate):

AUD 1.00
FX rate (in format AUD rate/primary
currency rate) Primary Currency rate
NZD 1.22000000
Will these +securities rank equally in all respects from their issue date with
the existing issued +securities in that class?
Yes
Yes
No
Existing class
No

Appendix 3B - Proposed issue of securities
Appendix 3B - Proposed issue of securities
8 / 8
Part 7C - Timetable
7C.1 Proposed +issue date
15/5/2026
Part 7D - Listing Rule requirements
7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?
7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?
Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue?
7E.2 Is the proposed issue to be underwritten?
7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue
Standard legal, registry costs and corporate advisory fees to Cameron Partners in line with customary levels for
transactions of this nature.
Part 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
Funds will be used to strengthen the balance sheet to support ongoing operations and growth, support the company to
achieve Medicare recoverage, and continue evidence generation, product development and innovation.
7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?
7F.2 Any other information the entity wishes to provide about the proposed issue
7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with
the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
An applicable ASIC instrument or class order
No
No
No
No
No